BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Multiple myeloma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for multiple myeloma: 297 (112 sponsors; 34 newly posted in the last 180 days, 9 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 14.6, rank 45 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 6, Phase 1 82, Phase 2 96, Phase 3 71, Phase 4 5, N/A 37.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Janssen Research & Development, LLC | 33 | P1 10, P3 12, P2 10, P4 1 | 2 | 3 |
| GlaxoSmithKline | 20 | P2 9, P3 7, P1 4 | 3 | 0 |
| AbbVie ABBV | 17 | P3 5, P1 7, P2 5 | 1 | 1 |
| Pfizer PFE | 12 | P3 4, NA 4, P1 2, P4 2 | 2 | 2 |
| Regeneron Pharmaceuticals REGN | 12 | P4 1, P2 7, P1 1, P3 3 | 1 | 0 |
| Sanofi SNY | 8 | P2 4, P3 3, P1 1 | 0 | 2 |
| AstraZeneca AZN | 7 | P1 1, P2 3, P3 3 | 3 | 0 |
| Celgene | 6 | P2 3, P3 3 | 0 | 2 |
| Qilu Pharmaceutical Co., Ltd. | 6 | P2 1, P3 3, P1 2 | 1 | 0 |
| Kite, A Gilead Company | 5 | P2 1, P1 1, P3 3 | 2 | 1 |
| Bristol-Myers Squibb BMY | 8 | NA 4, P3 2, P2 1, P1 1 | 0 | 1 |
| Keymed Biosciences Co.Ltd | 3 | P3 2, P2 1 | 1 | 1 |
| Alexion Pharmaceuticals, Inc. | 2 | P3 2 | 0 | 0 |
| Hoffmann-La Roche | 5 | P2 3, P1 1, P3 1 | 1 | 1 |
| Nanjing IASO Biotechnology Co., Ltd. | 5 | P1 2, P2 1, NA 1, P3 1 | 0 | 0 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 4 | P3 1, P2 3 | 0 | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 4 | P2 1, P3 1, P1 2 | 0 | 0 |
| Takeda TAK | 4 | NA 3, P3 1 | 0 | 2 |
| CellCentric Ltd. | 3 | P2 2, P3 1 | 1 | 1 |
| Hangzhou Sumgen Biotech Co., Ltd. | 3 | P1 1, P2 1, P3 1 | 0 | 1 |
| Innovent Biologics (Suzhou) Co. Ltd. | 3 | P2 2, P3 1 | 2 | 1 |
| Biocad | 2 | P2 1, P3 1 | 1 | 0 |
| Shandong New Time Pharmaceutical Co., LTD | 2 | P3 1, P2 1 | 0 | 0 |
| Shanghai Henlius Biotech | 2 | P3 1, P1 1 | 0 | 0 |
| BioLineRx, Ltd. BLRX | 1 | P3 1 | 0 | 0 |
Recently stopped trials
- NCT06055075 Hoffmann-La Roche - terminated: The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig. A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participant
- NCT04401020 Sanofi - terminated: Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
- NCT04649073 Otsuka Pharmaceutical Co., Ltd. - terminated: This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II. Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
- NCT04318327 Novartis Pharmaceuticals - terminated: Business decision BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
- NCT04855136 Celgene - terminated: Business objectives have changed Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
- NCT07428369 Regeneron Pharmaceuticals - withdrawn: Sponsor Decision A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- NCT07195617 Guangzhou Bio-gene Technology Co., Ltd - withdrawn: Due to corporate strategic adjustment. Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Mult
- NCT07196124 Guangzhou Bio-gene Technology Co., Ltd - withdrawn: Due to corporate strategic adjustment. BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
- NCT05839626 Sanofi - terminated: Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated. A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRM
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Celgene | NCT03989414 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in | Multiple Myeloma | active not recruiting | 424 |
| 2026-11-30 est. | P1/P2 | OriCell Therapeutics Co., Ltd. | NCT06182696 OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Relapsed and/or Refractory Multiple Myeloma | recruiting | 83 |
| 2026-12 est. | P1/P2 | Keymed Biosciences Co.Ltd | NCT05299424 A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 48 |
| 2026-12 est. | P2 | Kite, A Gilead Company | NCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Multiple Myeloma | active not recruiting | 136 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04271644 BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse | recruiting | 80 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04776330 a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse | recruiting | 80 |
| 2026-12-31 est. | P2 | GeoVax, Inc. GOVX | NCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myel | active not recruiting | 63 |
| 2026-12-31 est. | P1/P2 | Zhejiang ACEA Pharmaceutical Co. Ltd. | NCT05565807 Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | recruiting | 84 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07764861 A Open-Label Phase in Participants With Multiple Myeloma | Multiple Myeloma | not yet recruiting | 120 |
| 2027-01-10 est. | P3 | Celgene | NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or | Relapsed or Refractory Multiple Myeloma | recruiting | 810 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | BeOne Medicines ONC | NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, an | Relapsed/Refractory Multiple Myeloma | recruiting | 246 |
| 2026-10-31 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06083207 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 116 |
| 2026-10-12 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refract | Multiple Myeloma | recruiting | 260 |
| 2026-09-28 est. | P3 | Bristol-Myers Squibb BMY | NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relaps | Relapsed or Refractory Multiple Myeloma | active not recruiting | 606 |
| 2026-09-11 | P3 | Guangzhou Gloria Biosciences Co., Ltd. | NCT06514508 Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | Multiple Myeloma | recruiting | 60 |
| 2026-08-26 | P3 | Pfizer PFE | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatment | Multiple Myeloma | recruiting | 492 |
| 2026-08 est. | P3 | AbbVie ABBV | NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Partici | Multiple Myeloma | active not recruiting | 265 |
| 2026-07-31 est. | P1/P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT07090954 A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Multiple Myeloma | not yet recruiting | 32 |
| 2026-07-31 | P2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | NCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 230 |
| 2026-06-22 est. | P2 | Cellectar Biosciences, Inc. CLRB | NCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lym | active not recruiting | 120 |
| 2026-06-20 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma | unknown | 312 |
| 2026-05-31 est. | P2 | US Oncology Research | NCT04782687 Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Multiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomat | active not recruiting | 73 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "multiple myeloma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.